23andMe pivots from drug discovery to GLP-1 weight-loss prescriptions
The consumer genetics company is shifting its business toward prescribing incretin weight-loss drugs rather than developing its own therapeutics.
TR
By Tom Reyes · Markets Editor
Oct 12 12:15 ETSource: Olhar Digital
The wire
- 01Reporting says 23andMe is moving away from drug discovery and toward a GLP-1 weight-loss prescription business.
- 02The shift adds another consumer-facing entrant to the telehealth channel that clinicians and pharmacies already compete with for GLP-1 patients.
- 03No details on pricing, pharmacy partners or launch timing are given in the item.
From the source
Read at olhardigital.com.br23andme trades drug discovery for glp-1 weight loss prescriptions
